<DOC>
	<DOCNO>NCT01335035</DOCNO>
	<brief_summary>This study design establish efficacy safety deferasirox patient iron overload 6 18 month allogeneic hematopoietic stem cell transplant ( HSCT ) . The purpose study assess mean change serum ferritin 52 week treatment deferasirox , patient iron overload ( define serum ferritin level ≥ 1000 ng/ml receive &gt; 20 RBC concentrate ) allogeneic HSCT .</brief_summary>
	<brief_title>Open-Label Single-Arm Pilot Study Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Male female patient 18 year age old Patients undergo allogeneic HSCT 6 18 month prior inclusion . Patients screen ANC &gt; 1000/mm3 ferritin value ≥ 1000 ng/mL ( ferritin value must measure two measurement oneweek interval ) . Patients receive least 20 RBC concentrate unit 100mL/kg RBC life . Patients give informed consent ( prior performing study procedure ) Haemosiderosis related transfusion . Patients concomitant active malignancy . Active known viral hepatitis know HIVpositive . Mean level alanine aminotransferase ( ALT ) &gt; 5x ULN Treatment iron chelate agent allogeneic HSCT . Uncontrolled hypertension . Other protocoldefined inclusion/exclusion criterion may app</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Iron metabolism ,</keyword>
	<keyword>Allogenetic Hematopoietic Stem Cell Transplant ,</keyword>
	<keyword>haematological disease</keyword>
</DOC>